demonstrates that the ENO1‐specific monoclonal antibody, HuL227, inhibits the growth and invasiveness of prostate cancer cells and reduces inflammatory monocyte recruitment and angiogenesis within the TME.[71] Additionally, multiple studies have reported that ENOblock, along with ENO1 autoantibodies, reduces tumor cell growth and migration in various cancers by inhibiting ENO1.[38, 72, 73] Here, we obtained the ENO1 structure from the PDB Database and identified several ENO1 inhibitors in the PubChem Database. Here, ENO1 is linked to neoplasm.